Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CureVac N.V is a biotechnology business based in the US. CureVac N-V shares (CVAC) are listed on the NASDAQ and all prices are listed in US Dollars. CureVac N-V employs 500 staff and has a market cap (total outstanding shares value) of USD$15.6 billion.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$36.15 - USD$151.8 |
---|---|
50-day moving average | USD$100.5666 |
200-day moving average | USD$79.7225 |
Wall St. target price | USD$84.26 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$-10,400,000 |
---|---|
Return on assets TTM | -51.16% |
Return on equity TTM | 0% |
Profit margin | -215.46% |
Book value | N/A |
Market capitalisation | USD$15.6 billion |
TTM: trailing 12 months
There are currently 1.0 million CureVac N-V shares held short by investors – that's known as CureVac N-V's "short interest". This figure is 52.2% up from 672,026 last month.
There are a few different ways that this level of interest in shorting CureVac N-V shares can be evaluated.
CureVac N-V's "short interest ratio" (SIR) is the quantity of CureVac N-V shares currently shorted divided by the average quantity of CureVac N-V shares traded daily (recently around 1.1 million). CureVac N-V's SIR currently stands at 0.95. In other words for every 100,000 CureVac N-V shares traded daily on the market, roughly 950 shares are currently held short.
However CureVac N-V's short interest can also be evaluated against the total number of CureVac N-V shares, or, against the total number of tradable CureVac N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CureVac N-V's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 CureVac N-V shares in existence, roughly 10 shares are currently held short) or 0.015% of the tradable shares (for every 100,000 tradable CureVac N-V shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CureVac N-V.
Find out more about how you can short CureVac N-V stock.
We're not expecting CureVac N-V to pay a dividend over the next 12 months.
CureVac N. V. , a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others, as well as a collaboration with the U.
Steps to owning and managing TREB-U, with 24-hour and historical pricing before you buy.
Steps to owning and managing TIG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDAC, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB-WS, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TACT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TROX, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVG, with 24-hour and historical pricing before you buy.